As of August 28, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) has a DilutionWatch DilutionScore of 69/100, rated HIGH dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Apimeds Pharmaceuticals US, Inc. has a market capitalization of $21.28M, 1.51M shares outstanding, 6 institutional holders tracked.
This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.
Score Breakdown
📊Float Risk—
Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
model est. 42%
💰 Capital Raise
model 55%
• Critical: only 2.4 months cash remaining
🔁 Convertible Conversion
model 40%
• Significant convertible debt: 23% potential dilution
• Elevated convertible risk (60/100)
🔄 Reverse Split
model est. 15%
• Only 2 months cash — financial pressure
Market Data
Market Cap$21.28M
Shares Outstanding1.51M
FloatN/A
Cash$1.78M
Debt$20.0K
Short InterestN/A
Institutional Holdings
QoQ: ↑ 37.6% shares (2026Q1 vs prior)
6 institutional holders · 544.7K shares
#1
Hemenway Trust Co LLC
274.0K shares
#2
VANGUARD CAPITAL MANAGEMENT LLC
191.9K shares
#3
GEODE CAPITAL MANAGEMENT, LLC
40.1K shares
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Short Interest26.8K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jul 31, 2026
Recent SEC Activity
xbrl
XBRL WARRANT
2025-12-31
xbrl
XBRL CONVERTIBLE
2025-12-31
Full SEC filing analysis available with free account
→
Recent News
No recent news
Factual APUS Dilution Snapshot
Apimeds Pharmaceuticals US, Inc. (APUS) has a DilutionScore of 69/100, rated High dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for APUS: xbrl on 2025-12-31; xbrl on 2025-12-31.
- Score coverage note: Float Risk is excluded because public-float data is unavailable.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Track APUS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking APUS — Free
Real-time SEC alerts
DilutionScore™ tracking
No credit card required
Score Coverage Note
- Float Risk is excluded because public-float data is unavailable.